Can we use gonadotropin plasma concentration as surrogate marker for BMI-related incomplete estrogen suppression in breast cancer patients receiving anastrozole?

BACKGROUND: BMI has been suggested to impact on estrogenic activity in patients receiving anastrozole resulting in a reduced treatment efficacy in obese women. Current evidence in this regard is controversially discussed. Since estradiol is inversely correlated with gonadotropins it can be assumed t...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:BMC Cancer
Autors principals: Oberguggenberger, A., Meraner, V., Sztankay, M., Beer, B., Weigel, G., Oberacher, H., Kemmler, G., Czech, T., Holzner, B., Wildt, L., Sperner-Unterweger, B., Daniaux, M., Hubalek, M.
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2017
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5371265/
https://ncbi.nlm.nih.gov/pubmed/28351392
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-017-3208-6
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars